logo.jpg
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
June 17, 2021 09:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP)...
Fibrogen_US_Primary_logo_RGB_M01.jpg
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
June 16, 2021 08:00 ET | FibroGen, Inc
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM...
AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting
June 10, 2021 12:54 ET | AB Science
PRESS RELEASE RESULTS FROM MASITINIB STUDY AB12005 IN PANCREATIC CANCER PRESENTED AT THE ASCO ANNUAL MEETING WITH THE FULL ABSTRACT PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY Paris, 10...
AB Science annonce aujourd'hui que les résultats de l’étude AB12005 du masitinib dans le cancer du pancréas ont été présentés à la réunion annuelle 2021 de l'ASCO
June 10, 2021 12:54 ET | AB Science
COMMUNIQUE DE PRESSE PRESENTATION DES RESULTATS DE L’ETUDE AB12005 DU MASITINIB DANS LE CANCER DU PANCREAS A LA REUNION ANNUELLE DE L’ASCO ET PUBLICATION DU RESUME COMPLET DE L’ETUDE DANS LE...
Algernon Logo 1.png
Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil
June 03, 2021 07:00 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has initiated a new...
Rafael logo.png
Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program
May 26, 2021 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Sunshine Biopharma Logo
Sunshine Biopharma’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types
May 25, 2021 08:00 ET | Sunshine Biopharma Inc.
MONTREAL, May 25, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
AB Science today announced that results from masitinib study AB12005 in pancreatic cancer, have been selected for presentation at the upcoming ASCO Annual Meeting
May 20, 2021 12:07 ET | AB Science
PRESS RELEASE RESULTS FROM MASITINIB STUDY AB12005 IN PANCREATIC CANCER SELECTED FOR PRESENTATION AT THE ASCO ANNUAL MEETING Paris, May 20, 2021, 6pm CET AB Science SA (Euronext - FR0010557264 -...
AB Science annonce aujourd'hui que les résultats de l’étude AB12005 du masitinib dans le cancer du pancréas ont été sélectionnés pour être présentés à la prochaine réunion annuelle de l'ASCO.
May 20, 2021 12:07 ET | AB Science
COMMUNIQUE DE PRESSE SELECTION POUR PRESENTATION A LA REUNION ANNUELLE DE L’ASCO DES RESULTATS DE L’ETUDE AB12005 DU MASITINIB DANS LE CANCER DU PANCREAS Paris, 20 mai 2021, 18h AB Science SA...
Sunshine Biopharma Logo
Sunshine Biopharma Eliminates $250,000 in Variable Rate Convertible Debt and Provides an Update on Status of OTCQB Uplisting
May 20, 2021 08:00 ET | Sunshine Biopharma Inc.
MONTREAL, May 20, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...